Monitor the H2 ramp implied by maintained full-year EPS guidance ($1.91-$2.11) given Q1 non-GAAP EPS of $0.53 and Q2 of $0.02. The innovative brand growth trajectory (43% LC YoY) and raised brand outlook suggest underlying business momentum. Key catalysts: olanzapine LAI launch in Q4 2026, duvakitug Phase 3 updates, and the NYSE direct listing in September. The generics erosion (especially lenalidomide) remains a headwind to watch.
Drugs in focus
TEVA drug pipeline →AUSTEDO
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already on the market — first approved April 2017; Austedo XR approved February 2023
- Next catalyst
- None dated
What to watchAustedo is a mature, approved revenue driver for Teva, commercial execution and growth trajectory matter more than any single catalyst. Watch Teva's quarterly innovative brand revenue growth rate (43% LC YoY in H1 2026) and any label-expansion trial updates for downward drift potential, as the binary approval catalysts are years past.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 29 $34.71entry
- T+1 · 4mo ago +2.02%α +0.34% · $35.41
- T+5 · 3mo ago +0.03%α −5.50% · $34.72
- T+20 · 3mo ago +9.25%α +4.23% · $37.92
- T+60 · 26d ago +15.85%α +11.12% · $40.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Teva reported Q2 2026 revenue of $4.14B (-1% YoY) and non-GAAP EPS of $0.02, both below consensus ($0.05). The headline GAAP loss of $0.49/share was driven by a $726M Emalex acquisition charge ($724M IPR&D). However, key innovative brands (AUSTEDO, AJOVY, UZEDY) collectively grew 43% YoY in local currency to over $1B, and the company raised its 2026 revenue outlook for all three brands. Full-year non-GAAP EPS guidance of $1.91-$2.11 was maintained, implying a strong H2 ramp. A credit rating upgrade to investment-grade BBB- by Fitch and the planned ADS-to-direct-listing conversion add to the positive narrative.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $4,142M, down 1% YoY ($4,176M) and 3% in local currency
- GAAP loss per share $0.49 vs $0.24 EPS in Q2 2025; includes $726M Emalex-related expenses
- Non-GAAP diluted EPS $0.02 vs $0.66 a year ago, also impacted by ($0.61)/share from Emalex
- Key innovative brands (AUSTEDO $696M, AJOVY $244M, UZEDY $77M) grew 43% LC YoY; 2026 revenue outlook raised to ~$3.7B combined
- Full-year 2026 guidance maintained: revenue $16.5-$16.85B, non-GAAP EPS $1.91-$2.11, FCF $2.0-$2.4B
- Fitch upgraded corporate credit rating to investment grade BBB-
- ADS program replaced with direct listing of ordinary shares on NYSE, effective September 14, 2026
- Emalex acquisition closed (ecopipam NDA submitted); pipeline advancing: duvakitug, olanzapine LAI, TEV-408
- Operating cash flow $411M, free cash flow $622M; debt $16.6B, leverage 68%
- Legal settlements and loss contingencies of $230M in Q2, including $117M antitrust provision and $49M opioid update
Financial Impact
Q2 revenue $4.14B vs consensus $4.03B (beat implied); non-GAAP EPS $0.02 vs consensus $0.05 (miss). GAAP loss $0.49 vs $0.24 EPS last year. Full-year guidance maintained.
Risk Factors
- Generics revenue decline (U.S. segment -31% YoY for generics) due to lenalidomide competition may persist
- Emalex integration costs and IPR&D charges could pressure near-term margins
- Legal exposure: opioid settlements and antitrust litigation provisions remain elevated ($230M in Q2)
- Foreign exchange volatility ($85M positive impact in Q2, but swings can be unpredictable)
- High debt load ($16.6B) with 68% leverage and 27% of debt maturing short-term
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-004974 |
| Document: f8k_072926.htm | 0001171843-26-004974 |
| Document: 0001171843-26-004974-index-headers.html | 0001171843-26-004974 |
| Document: 0001171843-26-004974-index.html | 0001171843-26-004974 |
| Document: 0001171843-26-004974.txt | 0001171843-26-004974 |
| 8-K Data (Synthetic) | 0001171843-26-004974 |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers